BAD HOMBURG, Germany, Jan. 9, 2026 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal disease, will accelerate its share buyback program and start the repurchase of the second tranche. The program – presented during the company's Capital Markets Day on June 17, 2025 – has a total volume of EUR 1 billion. Under the second tranche, the company plans to repurchase its own shares for a total amount of around EUR 415 million from January ...

Core Insights - Fresenius Medical Care AG reported continued revenue growth in Q3 2025, achieving a Group organic growth of 10% and an operating income margin of 11.7%, indicating strong operational and financial progress [1][6][26]. Financial Performance - Q3 2025 revenue reached EUR 4,885 million, a 3% increase year-on-year, with an 8% increase at constant currency and a 10% organic growth [1][8]. - Operating income for Q3 2025 was EUR 477 million, up 3% year-on-year, while operating income excluding special items grew by 22% to EUR 574 million [14][19]. - Net income increased by 29% to EUR 275 million in Q3 2025, with net income excluding special items rising by 36% to EUR 322 million [20][19]. Segment Performance - Care Enablement saw a significant operating income growth of 38%, reaching a margin of 7.6% [1][18]. - Value-Based Care revenue grew by 34% to EUR 576 million, driven by an increase in member months due to contract expansion [11][19]. - Care Delivery revenue decreased by 2% to EUR 3,402 million, impacted by divestitures, but showed a positive organic growth of 6% [8][13]. Strategic Initiatives - The FME Reignite strategy is advancing, with the launch of a share buyback program and an increase in ownership of Interwell Health [1][7]. - The FME25+ transformation program delivered EUR 47 million in sustainable savings in Q3 2025, contributing to a total of EUR 174 million in savings for the first nine months [3][19]. Capital Allocation - An initial share buyback program of EUR 1.0 billion was announced, with EUR 151 million spent on repurchasing 3.6 million shares by September 30, 2025 [7][24]. - The net leverage ratio improved to 2.6x in Q3 2025, reflecting effective capital management alongside share buybacks and investments in Value-Based Care [24][6]. Outlook - The company confirmed its fiscal 2025 outlook, expecting positive revenue growth and operating income growth excluding special items in the high-teens to high-twenties percent range [26][27].

Core Viewpoint - Fresenius Medical Care (FME) has initiated the first tranche of its EUR 1 billion share buyback program, aimed at enhancing shareholder value as part of its new capital allocation framework [1][2][3]. Group 1: Share Buyback Program - The initial share buyback program totals EUR 1 billion over two years, with the first tranche of up to EUR 600 million set to be completed by April 30, 2026 [1][7]. - The share buyback is a key component of the FME Reignite strategy, which focuses on value creation for shareholders [2][3]. - Regular updates on the share buyback program will be provided on the company's investor relations website [3]. Group 2: Company Overview - Fresenius Medical Care is the leading provider of products and services for individuals with renal diseases, serving approximately 4.2 million patients globally who undergo dialysis treatment [4]. - The company operates a network of 3,676 dialysis clinics, providing treatments for around 300,000 patients worldwide [4]. - Fresenius Medical Care is also a major supplier of dialysis products, including dialysis machines and dialyzers, and is listed on both the Frankfurt Stock Exchange and the New York Stock Exchange [4].

Core Points - Fresenius Medical Care (FME) is partnering with the Coordination of National Institutes of Health and Specialty Hospitals (CCINSHAE) in Mexico to extend High-Volume Hemodiafiltration (HighVolumeHDF) access to low-income patients without medical coverage [1][2] - The pilot program aims to provide chronic kidney disease patients with high-quality treatments that were previously inaccessible, marking a significant advancement in CKD care in Mexico [3] - The initiative has already provided HighVolumeHDF treatment to 240 new patients and 410 regular patients covered by insurance [5][11] Company Initiatives - A two-year contract has been signed to install 150 Fresenius Medical Care 5008S CorDiax systems in CCINSHAE centers in Mexico City and its metropolitan area [2] - The technology offers both standard hemodialysis and HighVolumeHDF, which has shown improved patient well-being and cost-effectiveness [4] - The company is committed to expanding HighVolumeHDF therapy to all markets, including the U.S., where it has received FDA clearance for its 5008X Hemodialysis System [9][10][11] Clinical Evidence - High-Volume Hemodiafiltration has been supported by clinical studies, including the CONVINCE Trial, which reported a 23% reduction in all-cause mortality for patients treated with HighVolumeHDF compared to standard high-flux hemodialysis [7]

Core Insights - Fresenius Medical Care (FMS) has launched the "FME Reignite" strategy aimed at achieving industry-leading profitability while optimizing capital structure and advancing innovation in renal care [1][7] - The strategy includes a significant expansion of the FME25 program, now called FME25+, targeting €1.05 billion in sustainable cost savings by 2027, which is a €300 million increase from previous goals [2] - The establishment of Value-Based Care (VBC) as a standalone segment is expected to enhance transparency and contribute to growth, having generated €1.8 billion in revenues in 2024 [3] Profitability and Operational Focus - The FME25+ program focuses on operational excellence and margin expansion, aiming for mid-teens operating income margin by 2030 across Care Delivery and Care Enablement segments [2] - The program enhances scalability, standardization, and efficiency across clinics and manufacturing sites, leveraging synergies to streamline service delivery while maintaining care quality [4] Capital Structure and Shareholder Value - A new capital allocation framework aims to balance reinvestment and shareholder returns, with plans to allocate €800 million to €1 billion annually for capital expenditures through 2030 [5][8] - Fresenius will initiate a €1 billion share buyback program over two years starting in 2025 and has committed to a dividend payout ratio of 30-40% [8] Technological Advancements - The upcoming U.S. launch of the 5008X CAREsystem, a next-generation dialysis machine, is a cornerstone of the strategy, expected to improve clinical outcomes and operational efficiencies [10][11] - The 5008X system has shown a 4.4% mortality reduction over 2.5 years compared to conventional hemodialysis, promising lower hospitalization rates and improved treatment consistency [10] Competitive Positioning - Through the FME Reignite strategy, Fresenius is positioning itself as a financially disciplined, innovation-driven, and patient-centered leader in renal care, combining cost control with growth investments [12] - Compared to competitors like Baxter International, DaVita Inc., and Outset Medical, Fresenius has outperformed in share price, with a 19.8% increase year-to-date against the industry's decline of 12% [17]

Core Insights - Fresenius Medical Care reported strong operational and financial progress in Q1 2025, confirming its financial outlook for the full year [1][21] - The company achieved organic revenue growth in both segments, with Care Enablement expanding its operating income margin for the first time [1][6] - The FME25 transformation program delivered significant savings, contributing to improved earnings and margin growth [3][7] Financial Performance - Q1 2025 revenue increased by 3% year-on-year to EUR 4,881 million, with organic growth of 5% [2][6] - Operating income rose by 35% to EUR 331 million, with a margin of 6.8%, while net income more than doubled to EUR 151 million [2][17] - Basic earnings per share (EPS) increased by 113% to EUR 0.52, with EPS excluding special items rising by 31% to EUR 0.84 [2][17] Segment Performance - Care Delivery revenue increased by 2% to EUR 3,857 million, while Care Enablement revenue grew by 5% to EUR 1,367 million [8][11] - In the U.S., Care Delivery revenue rose by 6% to EUR 3,302 million, driven by a growing value-based care business [9] - International Care Delivery revenue declined by 19% to EUR 555 million, impacted by closed operations and a decrease in dialysis days [10] Cost Management and Savings - The FME25 program generated EUR 68 million in sustainable savings, with a target of EUR 180 million additional annual savings by year-end 2025 [3][7] - Special items related to portfolio optimization amounted to negative EUR 24 million in Q1 2025 [4][30] - Operating income excluding special items increased by 13% to EUR 457 million, resulting in a margin of 9.4% [13][30] Cash Flow and Leverage - Operating cash flow improved by 28% to EUR 163 million, with a margin of 3.3% [18] - Free cash flow increased to EUR 21 million, and total net debt was reduced to EUR 9,753 million, improving the net leverage ratio to 2.8x [19][19] Outlook - The company expects positive revenue growth in 2025, projecting operating income excluding special items to grow by a high-teens to high-twenties percent rate compared to the prior year [21][22]